CD8A and cancer: The above data suggest that a highly effective way to ameliorate the CD4-driven toxicity associated with CTLA4 and PD1 blockade in cancer treatment (8) would be to combine this therapy with blockade of OX40 and CD30 signals, for cancers where CD8 T cells were the main effectors of the anticancer response.